Ken Griffin Increases Holdings in AbbVie, Abbott Laboratories, and Eli Lilly
What happened
Ken Griffin increased his investment in AbbVie, Abbott Laboratories, and Eli Lilly. He bought 2.7 million shares of AbbVie, representing a 546% increase from the previous quarter. He also added 6.7 million shares of Abbott Laboratories, a 349% increase from Q1, and boosted his Eli Lilly stake by 291%.
From fool.com
Why it matters
The investment moves suggest a strategic focus on healthcare stocks, which notes tend to perform well during market downturns because healthcare is a necessity. AbbVie and Eli Lilly are direct competitors in the pharmaceutical market, vying for market share.
From fool.com
Who's involved
- Ken GriffinFounder and CEO of Citadel, making the investment moves.
- AbbViePharmaceutical company whose shares Ken Griffin increased his investment in.
- Eli Lilly and CompanyAmerican pharmaceutical company whose shares Ken Griffin boosted.
- CitadelInvestment firm founded and directed by Ken Griffin.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- VOOSpeculative
VOO might see its market price increase due to increased demand for Eli Lilly shares.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
- Ken Griffin
-
AbbVie
pharmaceutical company
-
Eli Lilly and Company
American pharmaceutical company
Related events
- AbbVie and Abbott Laboratories are large healthcare companies whose corporate histories are linked by a major split that occurred in 2013.
- AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.
- AbbVie's CEO, Robert A. Michael, is linked to pre-IPO investments, with Benzinga reporting financial data and Kevin O'Leary commenting on strategies.